SYNAGIS 50 mg/0.5 ml INJECTABLE SOLUTION
How to use SYNAGIS 50 mg/0.5 ml INJECTABLE SOLUTION
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Synagis 50 mg/0.5ml solution for injection
Synagis 100 mg/1 ml solution for injection
Active substance: palivizumab
Read all of this leaflet carefully before your child is given this medicine because it contains important information for you and your child
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of thepackage leaflet:
- What is Synagis and what is it used for
- What you need to know before your child is given Synagis
- How Synagis will be given to your child
- Possible side effects
- Storage of Synagis
- Contents of the pack and further information
1. What is Synagis and what is it used for
Synagis contains the active substance palivizumab, a monoclonal antibody that acts specifically against the respiratory syncytial virus (RSV).
Your child is at high risk of contracting an RSV infection.
Children who are more susceptible to contracting severe RSV disease (high-risk children) include premature babies (born at 35 weeks gestation or less) or babies with certain heart or lung problems.
Synagis is a medicine used to protect your child against this serious RSV disease.
2. What you need to know before your child is given Synagis
Your child should not be given Synagis
If they are allergic to palivizumab or any of the other ingredients of this medicine (listed in section 6). The signs and symptoms of a severe allergic reaction may include:
- severe rash, hives or itching of the skin
- swelling of the lips, tongue and face
- closure of the throat, difficulty swallowing
- blue discoloration of the skin, lips or under the nails
- muscle weakness or floppiness
- drop in blood pressure
- loss of consciousness
Warnings and precautions
Be careful with Synagis
Other medicines and Synagis
No interactions with other medicines have been observed with Synagis. However, before administration of Synagis, inform your doctor or pharmacist of all the medicines your child is taking.
3. How Synagis will be given to your child
How often will Synagis be given to your child?
Synagis should be administered in doses of 15 mg/kg of body weight, once a month during the time of RSV infection risk. For the best protection of your child, it is necessary to follow the doctor's instructions on when to receive the next doses of Synagis.
If your child undergoes heart surgery (surgical intervention with extracorporeal circulation), an additional dose of Synagis will be administered after the surgery. The initial injection program will then be continued.
How will your child receive Synagis?
Synagis should be administered to your child by injection into the muscle, normally in the outer part of the thigh.
What should you do if a dose of Synagis is missed?
If a dose is missed, you should talk to your child's doctor as soon as possible. Each Synagis injection can protect your child for about a month before another dose is needed.
Follow exactly the administration instructions indicated by your doctor or pharmacist. If you are unsure about how this medicine will be administered to your child, consult your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Synagis may cause serious side effects including:
- severe allergic reactions (such reactions can be life-threatening or fatal (see “Your child should not be given Synagis” for a list of signs and symptoms).
- unusual bruising or groups of small red spots on the skin.
Call your doctor or seek medical help immediately if your child experiences any of the serious side effects listed above after receiving a dose of Synagis.
Additional side effects
Very common (at least 1 in 10 patients):
- rash
- fever
Common (between 1 and 10 in 100 patients):
- pain, redness or swelling at the injection site
- pauses in breathing or other breathing difficulties
Uncommon (less than 1 in 100 patients):
- seizures
- hives
Reporting of side effects
If your child experiences any side effects, talk to your doctor, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Synagis
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label after “EXP”. The expiry date is the last day of the month shown.
Store in a refrigerator (between 2°C and 8°C).
Do not freeze.
Keep the vial in the original package to protect it from light.
6. Contents of the pack and further information
Composition of Synagis
- The active substance is palivizumab, one ml of Synagis solution for injection contains 100 mg of palivizumab.
- Each 0.5 ml vial contains 50 mg of palivizumab.
- Each 1 ml vial contains 100 mg of palivizumab.
- The other ingredients are histidine, glycine and water for injections.
Appearance and pack size
Synagis solution for injection is a clear and slightly opalescent solution and is available in 0.5 ml or 1 ml vials.
Pack size of 1.
Marketing authorisation holder
AstraZeneca AB
SE 151 85 Södertälje
Sweden
Manufacturer
AbbVie S.r.l.
04011 Campoverde di Aprilia (LT)
Italy
You can request more information about this medicine from the local representative of the marketing authorisation holder:
België/Belgique/Belgien AstraZeneca S.A./N.V. Tel: +32 2 370 48 11 | Lietuva UAB AstraZeneca Lietuva Tel: +370 5 2660550 |
???????? ??????????? ???????? ???? Te?.: +359 2 44 55 000 | Luxembourg/Luxemburg AstraZeneca S.A./N.V. Tél/Tel: +32 2 370 48 11 |
Ceská republika AstraZeneca Czech Republic s.r.o Tel: +420 222 807 111 | Magyarország AstraZeneca Kft. Tel.: +36 1 883 6500 |
Danmark AstraZeneca A/S Tlf: +45 43 66 64 62 | Malta Associated Drug Co. Ltd Tel: +356 2277 8000 |
Deutschland AstraZeneca GmbH Tel: +49 40 809034100 | Nederland AstraZeneca BV Tel: 31 85 808 9900 |
Eesti AstraZeneca Tel: +372 6549 600 | Norge AstraZeneca AS Tlf: +47 21 00 64 00 |
Ελλ?δα AstraZeneca A.E. Τηλ: +30 2 106871500 | Österreich AstraZeneca Österreich GmbH Tel: +43 1 711 31 0 |
España AstraZeneca Farmacéutica Spain, S.A. Tel: +34 91 301 91 00 | Polska AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 00 |
France AstraZeneca Tél: +33 1 41 29 40 00 | Portugal AstraZeneca Produtos Farmacêuticos, Lda. Tel: +351 21 434 61 00 |
Hrvatska AstraZeneca d.o.o. Tel: +385 1 4628 000 | România AstraZeneca Pharma SRL Tel: +40 21 317 60 41 |
Ireland AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7100 | Slovenija AstraZeneca UK Limited Tel: +386 1 51 35 600 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika AstraZeneca AB, o.z. Tel: +421 2 5737 7777 |
Italia AstraZeneca S.p.A. Tel: +39 02 00704500 | Suomi/Finland AstraZeneca Oy Puh/Tel: +358 10 23 010 |
Κ?προς Αλ?κτωρ Φαρµακευτικ? Λτδ Τηλ: +357 22490305 | Sverige AstraZeneca AB Tel: +46 8 553 26 000 |
Latvija SIA AstraZeneca Latvija Tel: +371 67377100 | United Kingdom(Northern Ireland) AstraZeneca UK Ltd Tel: +44 1582 836 836 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
------------------------------[perforation to separate from patient information]-------------------
This information is intended only for healthcare professionals:
Administration instructions
In order to improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.
Palivizumab should not be mixed with any other medicinal product or diluent.
Both the 0.5 ml and 1 ml vials contain an overfill to allow for the withdrawal of 50 mg or 100 mg, respectively.
Do not dilute the product.
Do not shake the vial.
To administer, remove the portion of the tab on the vial cap and clean the stopper with ethanol 70% or equivalent. Insert the needle into the vial and withdraw into the syringe the appropriate volume of solution. Palivizumab solution for injection does not contain preservatives, is for single use only and should be administered immediately after the dose has been drawn into the syringe.
Disposal of unused medicinal product or waste material should be in accordance with local requirements.
Palivizumab is administered once a month by intramuscular injection, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site due to the risk of injury to the sciatic nerve. The injection should be administered using a standard aseptic technique. Injection volumes greater than 1 ml should be administered in divided doses.
When using palivizumab 100 mg/1 ml, the volume of palivizumab (expressed in ml) to be administered once a month = (patient's weight in kg) multiplied by 0.15.
For example, the calculation for a 3 kg baby:
(3 x 0.15) ml = 0.45 ml of palivizumab per month.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to SYNAGIS 50 mg/0.5 ml INJECTABLE SOLUTIONDosage form: INJECTABLE, 100 mg/mLActive substance: palivizumabManufacturer: Astrazeneca AbPrescription requiredDosage form: INJECTABLE, 100 mgActive substance: nirsevimabManufacturer: Sanofi Winthrop IndustriePrescription requiredDosage form: INJECTABLE, 50 mgActive substance: nirsevimabManufacturer: Sanofi Winthrop IndustriePrescription required
Online doctors for SYNAGIS 50 mg/0.5 ml INJECTABLE SOLUTION
Discuss questions about SYNAGIS 50 mg/0.5 ml INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
